Johnson & Johnson’s combination of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) in certain patients with non-small cell lung cancer (NSCLC) stands to expand its use as a first-line treatment with the presentation of positive overall survival (OS) data from the Phase III MARIPOSA trial comparing it against AstraZeneca’s Tagrisso (osimertinib). And that’s even with Tagrisso’s relative convenience as an oral single agent.
Rybrevant/Lazcluze Survival Win Could Overcome Tagrisso’s Convenience Advantage
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
More from Immuno-oncology
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
Increasingly focused on maximizing and accelerating the progress of its PD-L1 x VEGF inhibitor BNT357, the company expects new partnerships to be announced this year.
• By
Sun is acquiring Checkpoint Therapeutics, opening up opportunities to build out its strategy in the onco-derm segment with the US firm’s FDA-approved anti-PD-L1 mAb.
More from Scrip
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.